Autopsy report · NCT03214666
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
Cause of deathFunding or business
“Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.”
Life of this trial
- Registered 2 years 6 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- GT Biopharma, Inc.
- Sponsor type
- Industry
- Conditions
- High-risk Myelodysplastic Syndromes; Acute Myelogenous Leukemia; Systemic Mastocytosis; Mast Cell Leukemia
- Interventions
- GTB-3550 TriKE® Phase I; GTB-3550 TriKE® Phase II
- Participants
- 12
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.